Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Confirm dangerous triglyceride elevation, prevent and recognise acute pancreatitis, reverse secondary drivers rapidly, and coordinate dietary, diabetes, lipid and genetic specialist treatment.
Triglycerides circulate in chylomicrons after meals and in liver-derived VLDL. Severe accumulation, especially of chylomicrons, makes serum visibly lipaemic and can trigger pancreatic inflammation. Concentrations fluctuate with food, alcohol and glycaemia, which is why NICE specifies a prompt fasting repeat in the 10-to-20 mmol/L range while secondary factors are addressed.
Most adult presentations are multifactorial: polygenic susceptibility plus uncontrolled diabetes, alcohol, central adiposity, pregnancy or a triglyceride-raising medicine. Familial chylomicronaemia syndrome is rare, often begins young, responds poorly to ordinary triglyceride medicines and causes recurrent pancreatitis; multifactorial chylomicronaemia is far more common. Eruptive xanthomata and recurrent unexplained pancreatitis are useful clues, not a genetic diagnosis.
Management separates pancreatitis prevention from atherosclerotic prevention. Very-low-fat nutrition, removal of alcohol, glycaemic control and specialist triglyceride-lowering therapy address chylomicrons. Once triglycerides permit reliable calculation, non-HDL, LDL and overall cardiovascular risk determine statin and adjunct use. Icosapent ethyl has a specific cardiovascular appraisal and should not be misrepresented as emergency treatment for chylomicronaemia.
Polygenic susceptibility combines with uncontrolled diabetes, alcohol, central adiposity, pregnancy or triglyceride-raising medicines to produce severe accumulation.
Rare inherited failure of chylomicron clearance often begins young, responds poorly to ordinary lipid medicines and causes recurrent pancreatitis.
Poor glycaemic control, hypothyroidism, kidney or liver disease and selected medicines can cause or amplify severe triglyceride elevation.
Excess production or impaired clearance raises chylomicrons and liver-derived VLDL, sometimes making serum visibly lipaemic as the process continues.
Large triglyceride-rich particles impair pancreatic microvascular flow and provide substrate for local free-fatty-acid release, promoting acinar-cell injury and inflammation.
Toxic free fatty acids and local ischaemia injure acinar tissue, triggering acute pancreatitis when the burden becomes severe.
Once extreme triglycerides fall, non-HDL cholesterol and the wider cardiovascular context determine residual atherosclerotic risk as the process continues.
Persistent severe epigastric pain radiating to the back with vomiting, ileus, tachycardia or hypotension requires emergency assessment; the triglyceride may fall after fasting, so obtain an early sample.
Crops of small yellow-red papules on extensor surfaces, buttocks or trunk can appear with marked chylomicronaemia and improve when triglycerides fall.
Creamy retinal vessels at extreme concentrations are a specialist clue to chylomicronaemia; vision may be relatively preserved, so fundal appearance should trigger systemic risk assessment.
Polyuria, thirst, weight loss, ketones, acidosis or very high glucose identifies insulin deficiency as a major cause; DKA requires immediate validated emergency treatment.
Onset in childhood or youth, recurrent pancreatitis, persistent extreme fasting triglycerides and poor response to standard therapy raises monogenic lipolysis-pathway disease and specialist testing.
Oestrogens, corticosteroids, retinoids, some antipsychotics, protease inhibitors and pregnancy can expose underlying susceptibility; abrupt stopping still requires indication and maternal safety review.
A recent meal can raise triglycerides transiently; a planned fasting repeat clarifies persistent severe disease when the person is clinically stable.
Marked hyperglycaemia and insulin deficiency increase hepatic triglyceride output and impair clearance, often improving substantially with metabolic control.
Childhood onset, recurrent pancreatitis, eruptive xanthomata and poor response to ordinary therapy favour a rare monogenic clearance defect.
Severe lipaemia can distort several assays, so discordant sodium or other biochemistry should be discussed with the laboratory.
Chylomicron accumulation can trigger severe pancreatic inflammation with abdominal pain, systemic inflammatory response and organ failure.
Persistent or relapsing severe triglycerides cause repeated pancreatitis, leading to chronic pain and exocrine or endocrine pancreatic dysfunction.
Atherogenic remnant and apoB-containing particles can coexist with chylomicrons, adding coronary, cerebral and peripheral vascular risk.
Triglycerides may fall quickly after pancreatitis stops oral intake, so an early pre-treatment lipid sample can preserve the causal clue.
Grossly turbid serum interferes with some sodium, amylase and other methods; warn the laboratory and interpret implausible results with analytical support.
Loss of effective insulin sharply reduces lipoprotein-lipase activity and increases hepatic triglyceride output, turning moderate inherited risk into extreme chylomicronaemia.
Preventing pancreatitis requires lowering triglyceride-rich chylomicrons, while preventing infarction focuses on apoB and LDL-related risk; one medicine rarely completes both jobs.
Most adults have multifactorial disease and respond to treating secondary causes; very early onset, recurrent pancreatitis and poor conventional response justify monogenic investigation.
Ignoring abdominal pain because the triglyceride result is still pending.
Waiting months to repeat a result between 10 and 20 mmol/L.
Calling one alcohol-related non-fasting sample familial chylomicronaemia.
Using statin monotherapy as sufficient protection against triglyceride pancreatitis.
Starting insulin infusion solely for a number without diabetes or specialist indication.
Combining gemfibrozil and statin without recognising major myopathy risk.
Prescribing an extreme fat restriction without dietetic nutritional safeguards.
Forgetting pregnancy and oestrogen exposure as major modifiers of severe triglycerides.
Your practice draft is saved in this browser.
An asymptomatic adult has a non-fasting triglyceride concentration of 14 mmol/L. What does NICE recommend as the next biochemical step?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Avoid severe renal or hepatic disease, gallbladder disease and pregnancy unless specialist-directed. Review creatinine, liver and muscle symptoms; statin combination increases myopathy risk, and formulations are not milligram-equivalent.
Do not run insulin solely to normalise triglycerides without specialist indication. Prevent hypoglycaemia and hypokalaemia, add glucose when protocol requires and never omit essential basal insulin in type 1 diabetes.
A statin is not adequate sole treatment for extreme chylomicronaemia. Avoid pregnancy, review liver and muscle risk, and take particular care when combined with a fibrate;
Eligibility, monitoring and available products can change. Follow product-specific platelet, hepatic, renal, injection and reproductive safeguards; it does not replace lifelong very-low-fat dietetic support.